Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
| Autor: | The OpenSAFELY Collaborative, Angel Y. S. Wong, Laurie A. Tomlinson, Jeremy P. Brown, William Elson, Alex J. Walker, Anna Schultze, Caroline E. Morton, David Evans, Peter Inglesby, Brian MacKenna, Krishnan Bhaskaran, Christopher T. Rentsch, Emma Powell, Elizabeth Williamson, Richard Croker, Seb Bacon, William Hulme, Chris Bates, Helen J. Curtis, Amir Mehrkar, Jonathan Cockburn, Helen I. McDonald, Rohini Mathur, Kevin Wing, Harriet Forbes, Rosalind M. Eggo, Stephen J. W. Evans, Liam Smeeth, Ben Goldacre, Ian J. Douglas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Adolescent medicine.drug_class Population Administration Oral Lower risk Direct oral anticoagulants Cohort Studies Young Adult Internal medicine Thromboembolism medicine Humans Diseases of the blood and blood-forming organs education Molecular Biology RC254-282 Aged Aged 80 and over education.field_of_study business.industry Proportional hazards model SARS-CoV-2 Research Hazard ratio Anticoagulant Warfarin Neoplasms. Tumors. Oncology. Including cancer and carcinogens COVID-19 Anticoagulants Atrial fibrillation Hematology Middle Aged medicine.disease COVID-19 Drug Treatment Treatment Outcome Oncology England RC633-647.5 business Cohort study medicine.drug |
| Zdroj: | Journal of Hematology & Oncology Wong, A Y S, Tomlinson, L A, Brown, J P, Elson, W, Walker, A J, Schultze, A, Morton, C E, Evans, D, Inglesby, P, MacKenna, B, Bhaskaran, K, Rentsch, C T, Powell, E, Williamson, E, Croker, R, Bacon, S, Hulme, W, Bates, C, Curtis, H J, Mehrkar, A, Cockburn, J, McDonald, H I, Mathur, R, Wing, K, Forbes, H, Eggo, R M, Evans, S J W, Smeeth, L & Goldacre, B & Douglas, I J 2021, ' Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants : population-based cohort study ', Journal of Hematology and Oncology, vol. 14, no. 1, 172 . https://doi.org/10.1186/s13045-021-01185-0 Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021) |
| ISSN: | 1756-8722 |
| Popis: | Background Thromboembolism has been reported as a consequence of severe COVID-19. Although warfarin is a commonly used anticoagulant, it acts by antagonising vitamin K, which is low in patients with severe COVID-19. To date, the clinical evidence on the impact of regular use of warfarin on COVID-19-related thromboembolism is lacking. Methods On behalf of NHS England, we conducted a population-based cohort study investigating the association between warfarin and COVID-19 outcomes compared with direct oral anticoagulants (DOACs). We used the OpenSAFELY platform to analyse primary care data and pseudonymously linked SARS-CoV-2 antigen testing data, hospital admissions and death records from England. We used Cox regression to estimate hazard ratios (HRs) for COVID-19-related outcomes comparing warfarin with DOACs in people with non-valvular atrial fibrillation. We also conducted negative control outcome analyses (being tested for SARS-CoV-2 and non-COVID-19 death) to assess the potential impact of confounding. Results A total of 92,339 warfarin users and 280,407 DOAC users were included. We observed a lower risk of all outcomes associated with warfarin versus DOACs [testing positive for SARS-CoV-2, HR 0.73 (95% CI 0.68–0.79); COVID-19-related hospital admission, HR 0.75 (95% CI 0.68–0.83); COVID-19-related deaths, HR 0.74 (95% CI 0.66–0.83)]. A lower risk of negative control outcomes associated with warfarin versus DOACs was also observed [being tested for SARS-CoV-2, HR 0.80 (95% CI 0.79–0.81); non-COVID-19 deaths, HR 0.79 (95% CI 0.76–0.83)]. Conclusions Overall, this study shows no evidence of harmful effects of warfarin on severe COVID-19 disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink